Eikonoklastes Therapeutics is an early stage biopharmaceutical company that is rapidly developing disruptive treatments for today's most challenging diseases. With a focus on neurodegenerative diseases and cancers, Eikonoklastes aims to significantly improve the lives of patients and families suffering from these devastating conditions. The company's approach is to break the mold by developing a pipeline of novel compounds tailored towards areas with the strongest benefit/risk, such as rare diseases and oncology.

They then collaborate with strategic partners to explore the immense potential in larger indications. Eikonoklastes is pushing the frontiers in areas of severe unmet clinical need, with a dynamic discovery and development approach that allows them to concentrate on accelerated approvals and outsized returns for multiple compounds. Their first two assets are on track for Phase 1/2a studies in 2023, and they have several additional therapies and potential partnerships on the horizon.

With a hyperfocus on breakthrough medicines, Eikonoklastes is dedicated to treating diseases with the highest unmet clinical need